Clinical Trials Sponsored by Molecure S.A.

Total 3174 results

BioTech Tools S.A.

Completed

Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis

Seasonal Allergic Rhinoconjunctivitis

Belgium
Ferrer Internacional S.A.

Completed

Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic Lesions

Secondarily Infected Traumatic Lesions

Germany
Laboratorios Goulart S.A.

Unknown

Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir (E01GOU-INH0109)

Boils | Acne Vulgaris II or III Degree

Brazil
Laboratoires Expanscience S.A.

Completed

Evaluation of the Structure Modifying Effect of Avocado-Soybean Unsaponifiables in Hip Osteoarthritis (ERADIAS)

Hip Osteoarthritis

France
Addex Pharma S.A.

Completed

ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)

Gastroesophageal Reflux

Austria, Belgium, France, Germany
Ache Laboratorios Farmaceuticos S.A.

Not yet recruiting

Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss (CAPELLI)

Alopecia
Fundació Eurecat
Euromed, S.A.

Not yet recruiting

Effect of Pomanox® on Skin Ageing (POMASKIN) (POMASKIN)

Skin Ageing

Spain
Clínica de Occidente S.A

Recruiting

Physical Exercise and Telephone Follow-up Mediated by Telerehabilitation

Cardiac Failure

Colombia
Endo Tools Therapeutics S.A.

Recruiting

Prospective Multicenter Study With the Endomina® Triangulation Platform (PRETTi)

Obesity

Belgium
Nyxoah S.A.
Nyxoah Inc.

Recruiting

Safety and Effectiveness of the Genio® bilAteral Stimulation for Treatment of Complete Concentric CollapsE and OSA. (ACCCESS)

Sleep Apnea, Obstructive

United States
Philip Morris Products S.A.

Terminated

Cross-Sectional Survey on the Use of Tobacco Products - Germany

Tobacco Use

Switzerland
Laboratorio Elea Phoenix S.A.

Completed

Racotumomab in Patients With High-risk Neuroblastoma

Neuroblastoma

Argentina
Ingredia S.A.
BioTeSys GmbH

Completed

Clinical Study to Assess the Long-term Effect of Pep2Dia® on Glucose Homeostasis in Prediabetic Subjects

Prediabetic State

Germany
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG

Smoking, Tobacco

United Kingdom
Bial - Portela C S.A.

Active, not recruiting

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs. (ADOPTION)

Parkinson Disease

Spain, Italy, Portugal, Germany, United Kingdom
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.

Smoking

Poland
Clínica de Occidente S.A

Completed

Efficacy Of An Education Plan And Adherence Follow-Up To The Exercise In Patients With Angioplasty And Stent Coronary

Patient Adherence

Colombia
Philip Morris Products S.A.

Completed

Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity

Smoking | Exercise Capacity

Germany
Roxall Medicina España S.A

Completed

Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma (ARES)

Rhinitis, Allergic | Rhinoconjunctivitis

Spain
Meiji Pharma Spain S.A.

Completed

Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia

COVID-19 Pneumonia

Spain
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics

Pulmonary Arterial Hypertension

Germany
Bial - Portela C S.A.

Completed

Relative Bioavailability and Bioequivalence of Opicapone

Parkinson Disease

United Kingdom
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil

Pulmonary Arterial Hypertension

Germany
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

Smoking

United States
Philip Morris Products S.A.

Completed

Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting

Smoking

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P

Pharmacokinetics

Switzerland
Philip Morris Products S.A.

Completed

Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants

Vaping | Nicotine Absorption

United States
Philip Morris Products S.A.

Completed

Exploratory THS 2.1 Biomarkers of Exposure Study (ZRHX-EX-01)

Smoking

Poland
Philip Morris Products S.A.

Completed

Exploratory THS 2.1 Nicotine Pharmacokinetics and Safety Study

Smoking

United Kingdom
Grünenthal GmbH
Grünenthal, S.A.

Withdrawn

Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate

Bioequivalence

Mexico
Ache Laboratorios Farmaceuticos S.A.

Suspended

Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu

Cold

Brazil
Ache Laboratorios Farmaceuticos S.A.

Withdrawn

Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain. (Delfos)

Low Back Pain
Roxall Medicina España S.A

Completed

Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)

Allergic Rhinoconjunctivitis

Spain
Ache Laboratorios Farmaceuticos S.A.

Suspended

Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks

Migraine

Brazil
Bial - Portela C S.A.

Completed

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Efficacy and Safety of Opicapone in Clinical Practice (OPTIPARK)

Parkinson's Disease With Wearing-off Motor Fluctuations

Germany
Ache Laboratorios Farmaceuticos S.A.

Unknown

Non-inferiority Evaluation of Pain Intensity After Biomatrop (Somatropin) Application in Relation to Hormotrop (Somatropin), in Healthy Subjects

Healthy Subjects

Brazil
Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Roxall Medicina España S.A

Completed

Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract

Allergic Rhinoconjunctivitis

Spain
Roxall Medicina España S.A

Completed

A Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Olea Europaea and Phleum Pratense

Rhinoconjuntivitis

Spain
Roxall Medicina España S.A

Completed

Biological Standardization of D. Glomerata, L. Perenne, S. Cereale and O. Europaea Pollen Extracts

Sensitization to Allergens

Spain
Roxall Medicina España S.A

Completed

Determination of Biological Activity of Three Allergen Extracts

Hypersensitivity

Spain
Bial - Portela C S.A.

Completed

Effect of Food on Opicapone

Parkinson Disease
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Hypertension

France
Bial - Portela C S.A.

Completed

Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects

Parkinson Disease

Germany
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France

3

Subscribe